GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » PB Ratio

KRBP (Kiromic BioPharma) PB Ratio : (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-13), Kiromic BioPharma's share price is $0.95. Kiromic BioPharma's Book Value per Share for the quarter that ended in Sep. 2024 was $-6.01. Hence, Kiromic BioPharma's PB Ratio of today is .

The historical rank and industry rank for Kiromic BioPharma's PB Ratio or its related term are showing as below:

During the past 6 years, Kiromic BioPharma's highest PB Ratio was 15.28. The lowest was 0.00. And the median was 0.00.

KRBP's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.48
* Ranked among companies with meaningful PB Ratio only.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Kiromic BioPharma was 48.60% per year. The lowest was 48.60% per year. And the median was 48.60% per year.

Back to Basics: PB Ratio


Kiromic BioPharma PB Ratio Historical Data

The historical data trend for Kiromic BioPharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma PB Ratio Chart

Kiromic BioPharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 5.47 0.87 - -

Kiromic BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiromic BioPharma's PB Ratio

For the Biotechnology subindustry, Kiromic BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiromic BioPharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's PB Ratio falls into.



Kiromic BioPharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Kiromic BioPharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=0.95/-6.008
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Kiromic BioPharma  (OTCPK:KRBP) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Kiromic BioPharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiromic BioPharma Business Description

Traded in Other Exchanges
N/A
Address
7707 Fannin Street, Suite 140, Houston, TX, USA, 77054
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.
Executives
Pietro Bersani director C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Brian Hungerford officer: CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Nagel director C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Michael Catlin director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark officer: Interim CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva director, officer: Chairman, CEO, and President 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan officer: Chief Technology Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez officer: See Remarks 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider director ONE VISION DRIVE, NATICK MA 01760
Scott Dahlbeck officer: Chief Medical Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino director, officer: CSIO 7707 FANNIN, SUITE 140, HOUSTON TX 77054

Kiromic BioPharma Headlines

From GuruFocus

Kiromic BioPharma CEO Issues Letter to Stockholders

By Business Wire Business Wire 02-16-2023